The Impact of Market Volatility on the Cell Therapy Industry
David Brindley(Orbus Therapeutics (United States)), Chris Mason(Oak Ridge National Laboratory), Emily J Culme-Seymour(GlaxoSmithKline (United Kingdom)), William A. Sahlman(Dana-Farber/Harvard Cancer Center), Greg A. Bonfiglio, Brock Reeve(Harvard Stem Cell Institute), Natasha L. Davie(Harvard University)
Cited by 30
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential
|Regenerative Medicine|2011|144
Peak Serum: Implications of Serum Supply for Cell Therapy Manufacturing
|Regenerative Medicine|2011|144